1. Market Research
  2. > Healthcare
  3. > General Medicine and Specialty Medicine Market Trends
  4. > EpiCast Report: Fabry Disease - Epidemiology Forecast to 2024

EpiCast Report: Fabry Disease - Epidemiology Forecast to 2024

Summary

Fabry disease is a rare X-linked inherited disorder caused by the deficiency of lysosomal enzyme a-galactosidase A (Nagueh, 2003). Fabry disease causes glycolipids such as globotriaosylceramide to accumulate in the vascular endothelium of skin, nervous system, heart and kidneys leading to inflammation and fibrosis resulting in organ dysfunction (Zarate and Hopkins, 2008). The organ dysfunction is regarded as the first clinical evidence of Fabry disease (Tsuboi et al., 2012). The symptoms of Fabry disease are typically severe in men, whereas women show variable range of symptoms with some being non symptomatic and others showing severe symptoms (Golfomitsos et al., 2012).

GlobalData epidemiologist forecast that the diagnosed prevalent cases of Fabry disease in the 7MM will increase from 4,538 diagnosed prevalent cases in 2014 to 8,037 diagnosed prevalent cases in 2024, at an AGR of 7.71% during the forecast period. Among the 7MM in 2024, the US will have the highest number of diagnosed prevalent cases of Fabry disease, with 3,540 diagnosed prevalent cases, whereas Spain will have the lowest number, with 523 diagnosed prevalent cases. In the 5EU, Germany will have the highest number of diagnosed prevalent cases of Fabry disease in 2024, with 819 diagnosed prevalent cases, and Spain will have the least number, with 523 diagnosed prevalent cases. Japan will have the highest AGR at 8.16%, while Germany will have the lowest AGR at 6.48%.

This report provides an overview of the risk factors, comorbidities/manifestations, and the global and historical epidemiological trends for Fabry disease in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK and Japan). It also includes a 10-year epidemiological forecast for the diagnosed prevalent cases of Fabry disease in these markets, segmented by age and sex. To construct the 10-year epidemiological forecast for the diagnosed prevalent cases of Fabry disease in the 7MM, GlobalData epidemiologists used data available from Fabry Support & Information Group (FSIG) for the US and the EU markets, and the data available for Japan from a population-based study conducted in Japan along with data available from FSIG for Asia-Pacific.

Scope

- The Fabry Disease EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for Fabry disease in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast of the diagnosed prevalent cases of Fabry disease segmented by sex, age (in five-year increments beginning at 0 years and ending at =85 years), and comorbidities in these markets.
- The Fabry Disease epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 10MM.

Reasons to buy

- Develop business strategies by understanding the trends shaping and driving the global Fabry disease market.
- Quantify patient populations in the global Fabry disease market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for Fabry disease therapeutics in each of the markets covered.

Table Of Contents

EpiCast Report: Fabry Disease - Epidemiology Forecast to 2024
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 5
2 Introduction 6
2.1 Catalyst 6
2.2 Related Reports 7
2.3 Upcoming Related Reports 7
3 Epidemiology 8
3.1 Disease Background 8
3.2 Risk Factors and Comorbidities/Manifestations 9
3.3 Global Trends 9
3.3.1 US 9
3.3.2 5EU 9
3.3.3 Japan 10
3.4 Forecast Methodology 10
3.4.1 Sources Used 11
3.4.2 Sources Not Used 12
3.4.3 Forecast Assumptions and Methods - Diagnosed Prevalent Cases 13
3.5 Epidemiological Forecast for Fabry disease (2014-2024) 15
3.5.1 Diagnosed Prevalent Cases of Fabry disease 15
3.5.2 Age-Specific Diagnosed Prevalent Cases of Fabry disease 16
3.5.3 Sex-Specific Diagnosed Prevalent Cases of Fabry disease 18
3.6 Discussion 20
3.6.1 Epidemiological Forecast Insight 20
3.6.2 Limitations of the Analysis 21
3.6.3 Strengths of the Analysis 22
4 Appendix 23
4.1 Bibliography 23
4.2 About the Authors 25
4.2.1 Epidemiologists 25
4.2.2 Reviewers 25
4.2.3 Global Director of Therapy Analysis and Epidemiology 26
4.2.4 Global Head of Healthcare 27
4.3 About GlobalData 28
4.4 About EpiCast 28
4.5 Disclaimer 29

1.1 List of Tables
Table 1: 7MM, Sources of Fabry Disease Diagnosed Prevalence Data 11
Table 2: 7MM, Diagnosed Prevalent Cases of Fabry Disease, All Ages, Both Sexes, N, Selected Years 2014-2024 15
Table 3: 7MM, Age-Specific Diagnosed Prevalent Cases of Fabry Disease, Both Sexes, N (Row %), 2014 17
Table 4: 7MM, Sex-Specific Diagnosed Prevalent Cases of Fabry Disease, All Ages, N (Row %), 2014 19

1.2 List of Figures
Figure 1: 7MM, Diagnosed Prevalent Cases of Fabry Disease, All Ages, Both Sexes, N, 2014-2024 16
Figure 2: 7MM, Age-Specific Diagnosed Prevalent Cases of Fabry Disease, Both Sexes, N, 2014 18
Figure 3: 7MM, Sex-Specific Diagnosed Prevalent Cases of Fabry Disease, All Ages, N, 2014 20

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Epiomic Epidemiology Series: Haemophagocytic lymphohistiocytosis (HLH) Forecast in 14 Major Markets 2016-2026

Epiomic Epidemiology Series: Haemophagocytic lymphohistiocytosis (HLH) Forecast in 14 Major Markets 2016-2026

  • $ 5112
  • Industry report
  • October 2016
  • by Black Swan Analysis Ltd132

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Haemophagocytic lymphohistiocytosis in 14 Major Markets Haemophagocytic lymphohistiocytosis (HLH) is an extremely rare haematological ...

Acute Respiratory Distress Syndrome - Epidemiology Forecast To 2023

Acute Respiratory Distress Syndrome - Epidemiology Forecast To 2023

  • $ 2750
  • Industry report
  • January 2017
  • by Delve Insight

DelveInsight “Acute Respiratory Distress Syndrome - Epidemiology Forecast To 2023” provides an overview of the epidemiology trends of Acute Respiratory Distress Syndrome in seven major markets (US, ...

Urinary Incontinence  - Epidemiology Forecast To 2023

Urinary Incontinence  - Epidemiology Forecast To 2023

  • $ 2750
  • Industry report
  • January 2017
  • by Delve Insight

DelveInsight “Urinary Incontinence  - Epidemiology Forecast To 2023” provides an overview of the epidemiology trends of Urinary Incontinence  in seven major markets (US, France, Germany, Italy, Spain, ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.